Clinical Trials Results, Financial Results, and Upcoming Earnings Releases- Research Report on Teleflex, Oxygen Biotherapeutics,

 Clinical Trials Results, Financial Results, and Upcoming Earnings Releases-
     Research Report on Teleflex, Oxygen Biotherapeutics, Novavax, Prana
                     Biotechnology and Hanger Orthopedic

PR Newswire

NEW YORK, November 4, 2013

NEW YORK, November 4, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Teleflex
Incorporated (NYSE: TFX), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT),
Novavax, Inc. (NASDAQ: NVAX), Prana Biotechnology Ltd. (NASDAQ: PRAN) and
Hanger Orthopedic Group Inc. (NYSE: HGR). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Teleflex Incorporated Research Report 

On October 30, 2013, Teleflex Inc. (Teleflex) announced its Q3 FY 2013 (period
ended September 29, 2013) financial results. The Company reported net revenues
totaling $413.8 million, up 12.4% YoY. GAAP diluted EPS from continuing
operations totaled $1.05 in Q3 FY 2013, compared to $0.58 in Q3 FY 2012.
Benson Smith, Chairman, President and CEO at Teleflex, commented, "Teleflex
delivered solid third quarter constant currency revenue growth and continued
to successfully execute on our initiatives to expand both gross and operating
margins. Our quarterly revenue performance was paced by continued strength in
Critical Care, which was aided by the contribution from our acquisition of LMA
International in 2012, an improvement in the average selling price of products
and the continued introduction of new products to the marketplace. In
addition, the third quarter results demonstrate the early benefit of our
actions focused on cost control to improve operating leverage in the
business." Teleflex stated that for full-year FY 2013, it anticipates constant
currency revenue growth to be between 8.5% and 10% and adjusted diluted
earnings per share in the range of $4.85 to $5.00. The Full Research Report on
Teleflex Incorporated - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9c7d_TFX]

Oxygen Biotherapeutics, Inc. Research Report 

On October 30, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) and
Phyxius Pharma, Inc. announced that researchers at the Duke Clinical Research
Institute have recently published findings of a meta-analysis of multiple
clinical trials that evaluated the use of levosimendan in patients undergoing
heart surgery. According to the Company, the results of the study showed that
levosimendan was associated with reduced mortality (death) and other adverse
outcomes including heart attacks during and after operation in patients with
reduced heart functions undergoing heart surgery. Oxygen Biotherapeutics
informed that the research was published in the Journal of Cardiothoracic and
Vascular Anesthesia as an "in Press" online version of the publication that
precedes the final publication. The Full Research Report on Oxygen
Biotherapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5700_OXBT]

Novavax, Inc. Research Report

On October 30, 2013, Novavax Inc. (Novavax) announced the schedule of its
earnings release and conference call. Novavax informed that it will host a
conference call and live webcast for reporting its Q3 2013 financial results
on Thursday, November 7, 2013 at 4:30 p.m. ET. The Company added that the
webcast and its replay can be accessed via its website under Investor
Info/Events section. The Full Research Report on Novavax, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/bc35_NVAX]

Prana Biotechnology Ltd. Research Report

On October 31, 2013, Prana Biotechnology (Prana) announced the publication of
an article in the peer reviewed journal Aging Cell, titled "A Novel Approach
To Rapidly Prevent Age-Related Cognitive Decline", showing the effects of its
drug, PBT2, on neurogenesis and in reversing the memory and learning losses
associated with the aging process, in normal (i.e. non transgenic) old mice.
Dr. Rudy Tanzi, Professor of Neurology at Harvard Medical School, Vice Chair
of Neurology at Massachusetts General Hospital, and Prana's Chief Scientific
Advisor, commented, "It is very exciting to discover that PBT2 not only helps
clear amyloid from the brain, but is promoting the birth of new nerve cells in
a part of the brain that is particularly affected by Alzheimer's disease, the
hippocampus. This now adds to the predicted beneficial properties of PBT2 for
the treatment and prevention of Alzheimer's disease." The Full Research Report
on Prana Biotechnology Ltd. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9f3a_PRAN]

Hanger Orthopedic Group Inc. Research Report

On October 29, 2013, Hanger, Inc. (Hanger) announced its Q3 2013 financial
results with net sales totaling $271.1 million, up 11.8% YoY. Adjusted diluted
EPS of the Company grew 24.0% YoY to $0.62 during the quarter. Hanger reported
income from operations of $39.9 million in Q3 2013, compared to $35.4 million
in Q3 2012. Commenting on the results, Vinit K. Asar, President and CEO of
Hanger, stated, "We are pleased with our revenue and earnings momentum in the
third quarter. We delivered strong same center sales growth of 3.8% in our
Patient Care segment and started to gain traction from our materials
management initiatives." The Company stated that for full-year 2013 it expects
its net sales to a range between $1.045 billion and $1.055 billion,
representing 7% and 8% YoY growth. The Full Research Report on Hanger
Orthopedic Group Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/0e96_HGR]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to making mistakes. If you notice any errors
    or omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)